Organo-arsenoxide compounds and use thereof
The present invention relates to organo-arsenoxide compounds and to methods for their synthesis. The invention also relates to pharmaceutical compositions comprising these compounds and to their use in the treatment of diseases and disorders, in particular proliferative diseases and disorders, including treatment of solid tumors and leukaemia.
1. A method of treating pancreatic cancer in a vertebrate, the method comprising administering to the vertebrate a therapeutically effective amount of a compound of general formula (I):
or a salt, enantiomer, or racemate thereof, wherein
the As(OH) 2 group is para- to the N-atom on the phenyl ring;
R 1 is selected from hydrogen and C 1-3 alkyl;
R 2 and R 3 are the same or different and are independently selected from hydrogen and optionally substituted C 1-3 alkyl;
R 4 and R 5 are the same or different and are independently selected from hydrogen and optionally substituted C 1-3 alkyl;
m is 1;
n is 1;
* indicates a chiral carbon atom; and
wherein each optional substituent is independently C 1-3 alkyl, C 1-3 alkoxy, halo, hydroxyl, or hydroxy(C 1-3 )alkyl.
2. The method according to claim 1 , wherein R 1 is selected from hydrogen, methyl and ethyl.
3. The method according to claim 1 , wherein R 1 is hydrogen.
4. The method according to claim 1 , wherein R 2 and R 3 are independently selected from hydrogen, C 1-3 alkyl, hydroxy(C 1-3 )alkyl and halo(C 1-3 )alkyl.
5. The method according to claim 1 , wherein R 2 and R 3 are independently selected from hydrogen, methyl, ethyl, hydroxymethyl, and CF 3 .
6. The method according to claim 1 , wherein R 2 and R 3 are independently selected from hydrogen, methyl and ethyl.
7. The method according to claim 1 , wherein R 2 and R 3 are both hydrogen.
8. The method according to claim 1 , wherein R 4 and R 5 are independently selected from hydrogen, C 1-3 alkyl, hydroxy-(C 1-3 )alkyl and halo(C 1-3 )alkyl.
9. The method according to claim 1 , wherein R 4 and R 5 are independently selected from hydrogen, methyl, ethyl, hydroxy(C 1-3 )alkyl, and CF 3 .
10. The method according to claim 1 , wherein R 4 and R 5 are independently selected from hydrogen, methyl, ethyl and hydroxymethyl.
11. The method according to claim 1 , wherein R 4 and R 5 are both methyl.
12. The method according to claim 1 , wherein the As(OH) 2 group is para- to the N-atom on the phenyl ring; R 1 is hydrogen or methyl; R 2 and R 3 are independently selected from hydrogen, C 1-3 alkyl, hydroxy(C 1-3 )alkyl and halo(C 1-3 )alkyl; R 4 and R 5 are independently selected from hydrogen, C 1-3 alkyl, hydroxy(C 1-3 )alkyl and halo(C 1-3 )alkyl; m is 1; and n is 1.
13. The method according to claim 1 , wherein the As(OH) 2 group is para- to the N-atom on the phenyl ring; R 1 is hydrogen or methyl; R 2 and R 3 are independently selected from hydrogen, methyl, ethyl, CH 2 OH, and CF 3 ; R 4 and R 5 are independently selected from hydrogen, methyl, ethyl, CH 2 OH, and CF 3 and OCF 3 ; m is 1; and n is 1.
14. The method according to claim 1 , wherein the As(OH) 2 group is para- to the N-atom on the phenyl ring; R 1 is hydrogen or methyl; R 2 and R 3 are independently selected from hydrogen, methyl and ethyl; R 4 and R 5 are independently selected from hydrogen, methyl and ethyl; m is 1; and n is 1.
15. The method according to claim 1 , wherein the As(OH) 2 group is para- to the N-atom on the phenyl ring; R 1 is hydrogen or methyl; R 2 is hydrogen or methyl; R 3 is hydrogen or methyl; R 4 is hydrogen, methyl or ethyl; R 5 is hydrogen or methyl; m is 1; and n is 1.
16. The method according to claim 1 , wherein the As(OH) 2 group is para- to the N-atom on the phenyl ring; R 1 is hydrogen; R 2 is hydrogen or methyl; R 3 is hydrogen; R 4 hydrogen or methyl; R 5 is hydrogen or methyl; m is 1; and n is 1.
17. The method according to claim 1 wherein the compound of general formula (I) has the following structural formula:
or a salt, enantiomer or racemate thereof.
18. The method according to claim 17 , wherein the stereochemistry at the chiral carbon denoted * is (S), or a salt thereof.
19. The method according to claim 1 wherein the compound inhibits angiogenesis in the vertebrate.
20. The method according to claim 1 wherein the compound selectively induces the MPT in proliferating cells in the vertebrate.
21. The method according to claim 1 wherein the compound induces apoptosis of the proliferating cells.
22. The method according to claim 1 , wherein the cells are endothelial cells.